COLO.B.DK

569.6

-0.14%↓

GMAB.DK

2,089

+3.06%↑

HLUNB.DK

45.28

+1.8%↑

ZEAL.DK

512.6

+1.75%↑

AMBUB.DK

107.1

+3.38%↑

COLO.B.DK

569.6

-0.14%↓

GMAB.DK

2,089

+3.06%↑

HLUNB.DK

45.28

+1.8%↑

ZEAL.DK

512.6

+1.75%↑

AMBUB.DK

107.1

+3.38%↑

COLO.B.DK

569.6

-0.14%↓

GMAB.DK

2,089

+3.06%↑

HLUNB.DK

45.28

+1.8%↑

ZEAL.DK

512.6

+1.75%↑

AMBUB.DK

107.1

+3.38%↑

COLO.B.DK

569.6

-0.14%↓

GMAB.DK

2,089

+3.06%↑

HLUNB.DK

45.28

+1.8%↑

ZEAL.DK

512.6

+1.75%↑

AMBUB.DK

107.1

+3.38%↑

COLO.B.DK

569.6

-0.14%↓

GMAB.DK

2,089

+3.06%↑

HLUNB.DK

45.28

+1.8%↑

ZEAL.DK

512.6

+1.75%↑

AMBUB.DK

107.1

+3.38%↑

Search

Novo Nordisk A-S (Class B)

Închisă

379 2.06

Rezumat

Modificarea prețului

24h

Curent

Minim

366.1

Maxim

382

Indicatori cheie

By Trading Economics

Venit

-2.5B

27B

Vânzări

-1.2B

77B

P/E

Medie Sector

13.758

35.739

EPS

5.96

Randament dividend

3.31

Marjă de profit

34.484

Angajați

78,387

EBITDA

44B

Recomandări

By TipRanks

Recomandări

Cumpărare

Prognoză pe 12 luni

+9.53% upside

Dividende

By Dow Jones

Randament dividend

Medie Sector

3.31%

3.08%

Următoarele câștiguri

5 nov. 2025

Statistici piață

By TradingEconomics

Capitalizare de piață

141B

1.5T

Deschiderea anterioară

376.94

Închiderea anterioară

379

Novo Nordisk A-S (Class B) Grafic

Performanțele din trecut nu reprezintă un indicator fiabil al rezultatelor viitoare.

Știri relevante

1 oct. 2025, 08:54 UTC

Principalele dinamici ale pieței

Pharma Stocks in Europe Jump After White House Unveils Drug-Buying Site

18 aug. 2025, 13:52 UTC

Principalele dinamici ale pieței

GoodRx Partners With Novo Nordisk to Lower Cost of Weight-Loss Drugs

18 aug. 2025, 09:23 UTC

Principalele dinamici ale pieței

Novo Nordisk Shares Rise After FDA Approves Wegovy for Liver Disease

18 aug. 2025, 09:23 UTC

Principalele dinamici ale pieței

Novo Nordisk Shares Rise After FDA Approves Wegovy for Liver Disease

6 aug. 2025, 06:52 UTC

Câștiguri

Novo Nordisk's Wegovy Weight-Loss Drug Sales Surge Despite Copycat Issues -- Update

6 aug. 2025, 06:21 UTC

Câștiguri

Novo Nordisk's Wegovy Weight-Loss Drug Sales Surge Despite Copycat Issues

1 oct. 2025, 09:05 UTC

Acțiuni populare

Stocks to Watch Wednesday: Nike, Lithium Americas, Arm, Occidental -- WSJ

29 sept. 2025, 12:04 UTC

Market Talk

Novo Nordisk Faces Headwind as U.S Obesity Drugs Stall, Competition Rises -- Market Talk

22 sept. 2025, 13:43 UTC

Achiziții, Fuziuni, Preluări

Pfizer to Buy Weight-Loss Drug Developer Metsera for Up to $7.3 Billion -- Update

18 sept. 2025, 12:30 UTC

Market Talk

Correction to Novo Nordisk Market Talk

18 sept. 2025, 12:00 UTC

Market Talk

Novo Nordisk's Prospects Could Turn Around -- Market Talk

18 sept. 2025, 08:55 UTC

Acțiuni populare

Stocks to Watch Thursday: Nvidia, PayPal, Novo Nordisk -- WSJ

11 sept. 2025, 10:59 UTC

Market Talk

Novo Nordisk Investors Cheer Plans to Slim Organization -- Market Talk

10 sept. 2025, 13:24 UTC

Câștiguri

Ozempic Maker Novo Nordisk to Cut 9,000 Jobs -- Update

10 sept. 2025, 09:16 UTC

Acțiuni populare

Stocks to Watch Wednesday: Oracle, GameStop, Novo Nordisk -- WSJ

2 sept. 2025, 09:14 UTC

Acțiuni populare

Stocks to Watch Tuesday: Nestlé, Novo Nordisk, Nvidia -- WSJ

21 aug. 2025, 08:49 UTC

Câștiguri
Acțiuni populare

Stocks to Watch Thursday: Meta, Coty, Walmart, Novo Nordisk -- WSJ

18 aug. 2025, 09:23 UTC

Acțiuni populare

Stocks to Watch Monday: Novo Nordisk, Soho House, UnitedHealth -- WSJ

8 aug. 2025, 05:32 UTC

Market Talk

Novo Nordisk's Weight-Loss Pill to Dominate Narrative After Eli Lilly's Data -- Market Talk

7 aug. 2025, 11:32 UTC

Câștiguri

Eli Lilly Stock Dives on Weight-Loss Pill Data as Earnings Beat Expectations. What to Know. -- Barrons.com

7 aug. 2025, 11:03 UTC

Câștiguri

Eli Lilly Stock Drops on Weight-Loss Pill Data as Earnings Beat Expectations. What to Know. -- Barrons.com

7 aug. 2025, 10:41 UTC

Câștiguri

Eli Lilly Stock Drops on Weight-Loss Pill Data Ahead of Earnings -- Barrons.com

6 aug. 2025, 20:34 UTC

Câștiguri

Eli Lilly Reports Earnings, and Maybe Weight-Loss Pill Data, on Thursday -- Barrons.com

6 aug. 2025, 08:45 UTC

Câștiguri

Novo Nordisk to Cut Costs After Stock Slump. Why Earnings Failed to Impress. -- Barrons.com

6 aug. 2025, 07:19 UTC

Market Talk
Câștiguri

Novo Nordisk Sales in Line, Boosted by One-Off Rebate -- Market Talk

6 aug. 2025, 05:50 UTC

Câștiguri

Novo Nordisk: Gudiance Assumes Macroeconomic, Political Environment Won't Significantly Change Business Conditions During 2025

6 aug. 2025, 05:48 UTC

Câștiguri

Novo Nordisk Declares Interim Dividend of DKK3.75 Vs DKK3.50

6 aug. 2025, 05:46 UTC

Câștiguri

Novo Nordisk Will Continue to Invest in Expanding Direct-to-Patient Initiatives For Wegovy

6 aug. 2025, 05:38 UTC

Câștiguri

Novo Nordisk 2Q Ozempic Drug Sales DKK31.8B Vs DKK28.88B

6 aug. 2025, 05:37 UTC

Câștiguri

Novo Nordisk 2Q Wegovy Drug Sales DKK19.53B Vs DKK11.66B

Comparație

Modificare preț

Novo Nordisk A-S (Class B) Așteptări

Obiectiv de preț

By TipRanks

9.53% sus

Prognoză pe 12 luni

Medie 1,162.73 DKK  9.53%

Maxim 1,550 DKK

Minim 720 DKK

În baza a 11 analiști de pe Wall Street care oferă obiective de preț pe 12 luni pentruNovo Nordisk A-S (Class B) - Dist în ultimele 3 luni.

Consens privind evaluarea

By TipRanks

Cumpărare

11 ratings

7

Cumpărare

2

Păstrare

2

Vânzare

Date financiare

Cheltuieli de vânzare și administrare

Cheltuieli de exploatare

Profit pre-impozitare

Vânzări

Costul vânzărilor

Profit brut din vânzări

Cheltuieli cu dobânzile pe datorie

EBITDA

Profit operațional

$

Despre Novo Nordisk A-S (Class B)

Novo Nordisk A/S, together with its subsidiaries, engages in the research and development, manufacture, and distribution of pharmaceutical products in Europe, the Middle East, Africa, Mainland China, Hong Kong, Taiwan, North America, and internationally. It operates in two segments, Diabetes and Obesity Care, and Rare Disease. The Diabetes and Obesity care segment provides products for diabetes, obesity, cardiovascular, and other emerging therapy areas. The Rare Disease segment offers products in the areas of rare blood disorders, rare endocrine disorders, and hormone replacement therapy. The company also provides insulin pens, growth hormone pens, and injection needles. In addition, it offers smart solutions for diabetes treatment, such as smart insulin pens and Dose Check, an insulin dose guidance application. The company has a collaboration agreement with UNICEF to tackle childhood obesity; and with Valo Health, Inc. to discover and develop novel drug programmes for cardiometabolic space. Novo Nordisk A/S was founded in 1923 and is headquartered in Bagsvaerd, Denmark.
help-icon Live chat